Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 407 results
Filters: Keyword is Male  [Clear All Filters]
Found 407 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

I

Stüve O, Marra CM, Jerome KR, et al. "Immune surveillance in multiple sclerosis patients treated with natalizumab." Ann. Neurol.. 2006;59(5):743-7.
Haas DW, Geraghty DE, Andersen J, et al. "Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: An AIDS Clinical Trials Group study." J. Infect. Dis.. 2006;194(8):1098-107.
Lok JJ, Hunt PW, Collier AC, et al. "The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy." AIDS. 2013;27(13):2101-10.
Coban H, Robertson K, Smurzynski M, et al. "Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen." AIDS. 2017;31(11):1565-1571.
Cillo AR, Krishnan S, McMahon DK, Mitsuyasu RT, Para MF, Mellors JW. "Impact of chemotherapy for HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy." PLoS ONE. 2014;9(3):e92118.
Marra CM, Zhao Y, Clifford DB, et al. "Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance." AIDS. 2009;23(11):1359-66.
Linas BP, Wang B, Smurzynski M, et al. "The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort." J. Viral Hepat.. 2011;18(7):506-12.
Parker RA, Rabideau DJ, Sax PE, et al. "Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study." Clin. Infect. Dis.. 2017;64(11):1612-1614.
Sacktor N, Miyahara S, Evans S, et al. "Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment." J. Neurovirol.. 2014;20(6):620-6.
Li JZ, Paredes R, Ribaudo HJ, et al. "Impact of minority nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure." J. Infect. Dis.. 2013;207(6):893-7.
Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT. "Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study." Clin. Infect. Dis.. 2012;55(5):631-8.
Erlandson KMace, Kitch D, Tierney C, et al. "Impact of randomized antiretroviral therapy initiation on glucose metabolism." AIDS. 2014;28(10):1451-61.
Aweeka FT, Rosenkranz SL, Segal Y, et al. "The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine." AIDS. 2006;20(14):1833-41.
Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM. "Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170." J. Acquir. Immune Defic. Syndr.. 2008;49(4):377-83.
Robertson K, Jiang H, Kumwenda J, et al. "Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study." Clin. Infect. Dis.. 2012;55(6):868-76.
Williams P, Wu J, Cohn S, et al. "Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution." HIV Med.. 2009;10(5):290-301.
Kshirsagar SA, Blaschke TF, Sheiner LB, Krygowski M, Acosta EP, Verotta D. "Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria." J Pharmacokinet Pharmacodyn. 2007;34(1):35-55.
Shire NJ, Rao MB, Succop P, et al. "Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection." Clin. Gastroenterol. Hepatol.. 2009;7(4):471-80, 480.e1-2.
Branch AD, Kang M, Hollabaugh K, Wyatt CM, Chung RT, Glesby MJ. "In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use." Am. J. Clin. Nutr.. 2013;98(2):423-9.
Krishnan S, Schouten JT, Jacobson DL, et al. "Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis." Oncology. 2011;80(1-2):42-9.
Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. "The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin." Aliment. Pharmacol. Ther.. 2011;33(11):1234-44.
Krishnan S, Wu K, Smurzynski M, et al. "Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis." HIV Clin Trials. 2011;12(4):190-200.
Taylor LE, Holubar M, Wu K, et al. "Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials." Clin. Infect. Dis.. 2011;52(6):812-8.
Robbins GK, Spritzler JG, Chan ES, et al. "Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384." Clin. Infect. Dis.. 2009;48(3):350-61.
McComsey GA, Kitch D, Daar ES, et al. "Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir." AIDS. 2012;26(11):1371-85.
Pence BWells, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ. "The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2008;47(2):194-201.
Haubrich RH, Riddler SA, Ribaudo H, et al. "Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection." AIDS. 2011;25(18):2269-78.
Gulick RM, Lalama CM, Ribaudo HJ, et al. "Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression." AIDS. 2007;21(7):813-23.
Manion M, Rodriguez B, Medvik K, et al. "Interferon-alpha administration enhances CD8+ T cell activation in HIV infection." PLoS ONE. 2012;7(1):e30306.
Skiest DJ, Su Z, Havlir DV, et al. "Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170." J. Infect. Dis.. 2007;195(10):1426-36.

Pages